Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
Palisade Bio, Inc. (PALI)
Company Research
Source: GlobeNewswire
– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases – Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end Carlsbad, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the launch of its new corporate branding and website, palisadebio.com and reiterated its commitment to stakeholders by advancing its lead product candidate, PALI-2108. “We remain committed to our mission of developing differentiated product candidates for immune, inflammatory and fibrotic
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative ColitisGlobeNewswire
- Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient StratificationGlobeNewswire
- Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
PALI
Sec Filings
- 9/27/24 - Form 8-K
- 8/12/24 - Form 10-Q
- 7/15/24 - Form 4
- PALI's page on the SEC website